X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | 2025-07-09 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Pres, R, D, 10% | S - Sale | $150.27 | -14,127 | 3,122,640 | 0% | -$2,122,835 | |||||
M | 2025-07-09 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Pres, CEO, 10% | S - Sale | $150.27 | -14,127 | 3,122,640 | 0% | -$2,122,835 | |||||
D | 2025-07-10 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $135.00 | -457 | 4,730 | -9% | -$61,695 | |||||
D | 2025-07-09 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale+OE | $15.00 | -495,282 | 2,455,675 | -17% | -$7,429,230 | |||||
D | 2025-07-09 | NBIX | Neurocrine Biosciences Inc | Onyia Jude | Chief Scientific Officer | S - Sale+OE | $130.46 | -59,819 | 18,289 | -77% | -$7,803,688 | |||||
2025-07-09 | IMVT | Immunovant, Inc. | Geffner Michael | Chief Medical Officer | S - Sale | $17.24 | -1,160 | 224,210 | -1% | -$19,998 | ||||||
2025-07-09 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $17.24 | -1,519 | 207,724 | -1% | -$26,188 | ||||||
2025-07-09 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $38.15 | -2,449 | 103,569 | -2% | -$93,420 | ||||||
2025-07-08 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $34.44 | -24,066 | 115,495 | -17% | -$828,898 | ||||||
DM | 2025-07-08 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $56.46 | -60,000 | 733,719 | -8% | -$3,387,517 | |||||
2025-07-09 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $3.57 | -61,379 | 1,652,191 | -4% | -$219,123 | ||||||
2025-07-08 | PROK | Prokidney Corp. | Weber Darin J. | Chief Regulatory Officer | S - Sale | $3.02 | -103,480 | 0 | -100% | -$312,510 | ||||||
2025-07-08 | MGTX | Meiragtx Holdings Plc | Forbes Alexandria | Pres, CEO | S - Sale | $7.97 | -47,500 | 1,361,483 | -3% | -$378,575 | ||||||
2025-07-03 | DTIL | Precision Biosciences Inc | Kelly John Alexander | CFO | S - Sale | $4.26 | -14,827 | 73,485 | -17% | -$63,163 | ||||||
D | 2025-07-07 | FENC | Fennec Pharmaceuticals Inc. | Rallis Chris A | Dir | S - Sale+OE | $8.71 | -1,119 | 54,792 | -2% | -$9,746 | |||||
2025-07-03 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $8.61 | -10,000 | 60,670 | -14% | -$86,100 | ||||||
D | 2025-07-02 | NBIX | Neurocrine Biosciences Inc | Onyia Jude | Chief Scientific Officer | S - Sale+OE | $130.13 | -20,362 | 18,289 | -53% | -$2,649,738 | |||||
2025-07-02 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $36.19 | -125 | 104,612 | 0% | -$4,524 | ||||||
2025-07-02 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $36.19 | -209 | 240,574 | 0% | -$7,564 | ||||||
D | 2025-07-02 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $36.19 | -476 | 645,306 | 0% | -$17,228 | |||||
2025-07-02 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $36.19 | -142 | 127,461 | 0% | -$5,139 | ||||||
D | 2025-07-02 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $45.09 | -10,090 | 238,998 | -4% | -$454,954 | |||||
2025-07-02 | CRGX | Cargo Therapeutics, Inc. | Radhakrishnan Anup | See Remarks | S - Sale | $4.18 | -1,632 | 120,781 | -1% | -$6,822 | ||||||
M | 2025-07-01 | BEAM | Beam Therapeutics Inc. | Simon Amy | Chief Medical Officer | S - Sale | $19.17 | -1,250 | 64,864 | -2% | -$23,962 | |||||
D | 2025-06-30 | BCDA | Biocardia, Inc. | McClung David | CFO | P - Purchase | $2.08 | +4,819 | 47,950 | +11% | +$9,999 | |||||
D | 2025-06-30 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.08 | +24,096 | 165,862 | +17% | +$49,999 | |||||
D | 2025-06-30 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $2.08 | +72,289 | 315,875 | +30% | +$150,000 | |||||
D | 2025-06-30 | BCDA | Biocardia, Inc. | Blank Andrew Scott | Dir | P - Purchase | $2.08 | +72,289 | 348,058 | +26% | +$150,000 | |||||
2025-07-02 | EXOZ | Exozymes Inc. | Heltzen Michael | CEO | P - Purchase | $10.22 | +1,040 | 10,629 | +11% | +$10,629 | ||||||
2025-07-01 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $5.10 | -22,000 | 1,298,391 | -2% | -$112,207 | ||||||
D | 2025-07-01 | ATHA | Athira Pharma, Inc. | Church Kevin | Chief Scientific Officer | S - Sale+OE | $0.29 | -8,526 | 168,901 | -5% | -$2,502 | |||||
D | 2025-07-01 | ATHA | Athira Pharma, Inc. | Litton Mark James | Pres, CEO | S - Sale+OE | $0.29 | -25,123 | 345,491 | -7% | -$7,374 | |||||
D | 2025-07-01 | ATHA | Athira Pharma, Inc. | San Martin Javier | CHIEF MEDICAL OFFICER | S - Sale+OE | $0.29 | -10,842 | 71,665 | -13% | -$3,182 | |||||
D | 2025-07-01 | ATHA | Athira Pharma, Inc. | Worthington Mark | GC, CCO | S - Sale+OE | $0.29 | -8,526 | 111,875 | -7% | -$2,502 | |||||
D | 2025-07-01 | ATHA | Athira Pharma, Inc. | Renninger Robert | SVP, Finance, Accounting | S - Sale+OE | $0.29 | -2,897 | 109,186 | -3% | -$850 | |||||
D | 2025-06-30 | CADL | Candel Therapeutics, Inc. | Nichols William Garrett | Chief Medical Officer | S - Sale+OE | $5.04 | -781 | 52,493 | -1% | -$3,936 | |||||
2025-06-27 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $30.47 | -200,000 | 3,657,349 | -5% | -$6,093,000 | ||||||
2025-06-30 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $110.45 | -10,000 | 615,725 | -2% | -$1,104,484 | ||||||
2025-06-30 | PRME | Prime Medicine, Inc. | Liu David R. | 10% | P - Purchase | $2.52 | +21,000 | 20,240,945 | 0% | +$52,830 | ||||||
D | 2025-04-28 | PLUR | Pluri Inc. | Manieu Alexandre Weinstein | Dir, 10% | P - Purchase | $4.61 | +976,139 | 1,394,198 | +233% | +$4,500,001 | |||||
D | 2025-06-30 | KYMR | Kymera Therapeutics, Inc. | Baker Bros. Advisors LP | Dir | P - Purchase | $44.00 | +655,500 | 6,117,295 | +12% | +$28,842,000 | |||||
2025-06-26 | CDTX | Cidara Therapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $44.00 | +2,272,727 | 3,365,523 | +208% | +$99,999,988 | ||||||
2025-06-25 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.00 | +6,000 | 416,371 | +1% | +$12,000 | ||||||
2025-06-25 | DTIL | Precision Biosciences Inc | Brown Melinda | Dir | P - Purchase | $4.14 | +1,682 | 20,565 | +9% | +$6,963 | ||||||
2025-06-25 | DTIL | Precision Biosciences Inc | Buehler Kevin | Dir | P - Purchase | $4.16 | +5,076 | 28,137 | +22% | +$21,116 | ||||||
M | 2025-06-24 | PASG | Passage Bio, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $0.34 | -583,657 | 6,066,343 | -9% | -$197,239 | |||||
D | 2025-06-23 | SRRK | Scholar Rock Holding Corp | Flier Jeffrey S. | Dir | S - Sale+OE | $32.58 | -31,452 | 35,206 | -47% | -$1,024,722 | |||||
DM | 2025-06-20 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $53.09 | -60,000 | 733,719 | -8% | -$3,185,280 | |||||
D | 2025-06-20 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $35.76 | -1,678 | 645,782 | 0% | -$59,997 | |||||
2025-06-20 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $35.76 | -292 | 127,603 | 0% | -$10,440 | ||||||
2025-06-20 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $35.76 | -230 | 104,737 | 0% | -$8,224 | ||||||
M | 2025-06-18 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.11 | +4,002 | 410,371 | +1% | +$8,425 | |||||
2025-06-23 | PRME | Prime Medicine, Inc. | Liu David R. | 10% | P - Purchase | $2.16 | +21,000 | 20,219,945 | 0% | +$45,402 | ||||||
2025-06-20 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $39.61 | -1,912 | 54,093 | -3% | -$75,736 | ||||||
2025-06-20 | ALEC | Alector, Inc. | Yaffe Kristine | Dir | S - Sale | $1.44 | -1,000 | 95,409 | -1% | -$1,440 | ||||||
M | 2025-06-18 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $30.19 | -334,801 | 3,857,349 | -8% | -$10,107,818 | |||||
D | 2025-06-16 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $20.81 | -21,000 | 3,768,233 | -1% | -$437,010 | |||||
D | 2025-06-17 | TARS | Tarsus Pharmaceuticals, Inc. | Farrow Jeffrey S | See Remarks | S - Sale+OE | $40.42 | -13,608 | 36,704 | -27% | -$550,035 | |||||
2025-06-16 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale | $39.83 | -3,510 | 150,675 | -2% | -$139,803 | ||||||
2025-06-16 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $39.83 | -13,496 | 935,172 | -1% | -$537,546 | ||||||
2025-06-16 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $39.83 | -1,878 | 56,005 | -3% | -$74,801 | ||||||
2025-06-16 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale | $39.83 | -2,170 | 113,314 | -2% | -$86,431 | ||||||
2025-06-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $39.83 | -4,289 | 289,414 | -1% | -$170,831 | ||||||
2025-06-16 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $33.48 | -94 | 104,967 | 0% | -$3,147 | ||||||
2025-06-16 | RVMD | Revolution Medicines, Inc. | Wei Lin | Chief Medical Officer | S - Sale | $39.83 | -2,173 | 90,499 | -2% | -$86,551 | ||||||
D | 2025-06-17 | KOD | Kodiak Sciences Inc. | Borgeson John A. | See Remarks | S - Sale+OE | $3.65 | -723 | 183,316 | 0% | -$2,640 | |||||
2025-06-16 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $110.17 | -2,500 | 165,110 | -1% | -$275,425 | ||||||
2025-06-16 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale | $110.17 | -3,000 | 120,168 | -2% | -$330,510 | ||||||
2025-06-16 | SRRK | Scholar Rock Holding Corp | Peng Katie | Dir | S - Sale | $31.97 | -3,031 | 34,920 | -8% | -$96,888 | ||||||
2025-06-16 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $32.00 | -3,668 | 139,561 | -3% | -$117,381 | ||||||
2025-06-16 | SRRK | Scholar Rock Holding Corp | Parlavecchio Caryn | CHRO | S - Sale | $32.00 | -6,186 | 157,642 | -4% | -$197,961 | ||||||
2025-06-16 | SRRK | Scholar Rock Holding Corp | Ho Junlin | GC | S - Sale | $32.00 | -7,442 | 222,569 | -3% | -$238,154 | ||||||
D | 2025-06-16 | TARS | Tarsus Pharmaceuticals, Inc. | Lin Elizabeth Yeu | Chief Medical Officer | S - Sale+OE | $41.08 | -1,006 | 35,600 | -3% | -$41,326 | |||||
DM | 2025-06-12 | ADMA | Adma Biologics, Inc. | Elms Steve | Dir | S - Sale+OE | $20.74 | -425,621 | 2,119,060 | -17% | -$8,829,333 | |||||
2025-06-16 | PRME | Prime Medicine, Inc. | Liu David R. | 10% | P - Purchase | $1.49 | +21,000 | 20,198,945 | 0% | +$31,196 | ||||||
D | 2025-06-13 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir, 10% | P - Purchase | $14.33 | +3,488 | 558,114 | +1% | +$49,983 | |||||
2025-06-13 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $7.70 | +107 | 38,885 | 0% | +$824 | ||||||
2025-06-11 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.00 | +524 | 406,369 | 0% | +$1,048 | ||||||
2025-06-12 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $8.70 | +103 | 38,675 | 0% | +$896 | ||||||
2025-06-11 | PRME | Prime Medicine, Inc. | Liu David R. | 10% | P - Purchase | $1.60 | +21,000 | 20,177,945 | 0% | +$33,590 | ||||||
2025-06-10 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $29.00 | -350,000 | 4,192,150 | -8% | -$10,150,000 | ||||||
2025-06-11 | MRNA | Moderna, Inc. | Hussain Abbas | Dir | S - Sale | $28.00 | -312 | 580 | -35% | -$8,736 | ||||||
2025-06-10 | ALLO | Allogene Therapeutics, Inc. | Messemer Deborah M. | Dir | S - Sale | $1.42 | -36,885 | 107,431 | -26% | -$52,377 | ||||||
2025-06-09 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $1.99 | +138 | 405,845 | 0% | +$275 | ||||||
DM | 2025-06-09 | ITOS | Iteos Therapeutics, Inc. | Detheux Michel | CEO | S - Sale+OE | $10.03 | -104,565 | 247,930 | -30% | -$1,048,264 | |||||
2025-06-09 | ADMA | Adma Biologics, Inc. | Guiheen Lawrence P. | Dir | S - Sale | $20.96 | -20,000 | 145,820 | -12% | -$419,200 | ||||||
D | 2025-06-10 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $67.36 | -1,500 | 0 | -100% | -$101,040 | |||||
2025-06-09 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $0.62 | -4,904 | 405,982 | -1% | -$3,050 | ||||||
2025-06-09 | IPSC | Century Therapeutics, Inc. | Farid Adrienne | Chief Operations Officer | S - Sale | $0.62 | -552 | 250,141 | 0% | -$343 | ||||||
2025-06-09 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | S - Sale | $0.62 | -475 | 1,681,783 | 0% | -$295 | ||||||
2025-06-09 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $0.62 | -526 | 484,820 | 0% | -$327 | ||||||
2025-06-09 | TARS | Tarsus Pharmaceuticals, Inc. | Mottiwala Aziz | Chief Commercial Officer | S - Sale | $43.76 | -17,500 | 47,557 | -27% | -$765,800 | ||||||
D | 2025-06-11 | KYMR | Kymera Therapeutics, Inc. | Ridloff Elena | Dir | S - Sale+OE | $50.00 | -4,500 | 0 | -100% | -$225,000 | |||||
D | 2025-06-09 | TECH | Bio-Techne Corp | Herr Amy E. | Dir | S - Sale+OE | $49.77 | -1,280 | 3,016 | -30% | -$63,705 | |||||
D | 2025-06-09 | ADMA | Adma Biologics, Inc. | Grossman Jerrold B | Dir | S - Sale+OE | $21.31 | -10,000 | 570,901 | -2% | -$213,100 | |||||
2025-06-06 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $31.75 | -257 | 105,061 | 0% | -$8,160 | ||||||
2025-06-06 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $31.75 | -853 | 127,895 | -1% | -$27,083 | ||||||
D | 2025-06-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $31.75 | -2,170 | 647,460 | 0% | -$68,898 | |||||
2025-06-06 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $31.75 | -225 | 49,966 | 0% | -$7,144 | ||||||
2025-06-06 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.00 | +11,100 | 405,707 | +3% | +$22,200 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |